Proxima AB has acquired Björkhagen Vårdcentral AB
Proxima AB, a Swedish private equity-owned medical care provider, has acquired Björkhagen Vårdcentral AB from the management team for an undisclosed consideration.
Proxima is a private healthcare group owned by CapMan, a private equity company listed on the Finnish stock exchange. Proxima is active in primary healthcare, diagnostics and specialist healthcare. Specialist healthcare is conducted in Nacka hospital, Motala hospital and the surgical clinic in Östermalm, Stockholm. "The acquisition of Björkhagens Vårdcentral is yet another step in our goal to offer our patients the best and most extensive local hospital care," said Thomas Andersson, CEO of Proxima primary care.
Björkhagen is located in the south of Stockholm, an area with large growth potential. The proximity to Nacka hospital, where Proxima conducts extensive specialist healthcare, will benefit patients. The healthcare center in Björkhagen was founded in 2001, when it was taken over by the county council.
Oaklins' team in Sweden advised the buyer in this transaction. This transaction is the first in a series of acquisitions following an initial strategic analysis resulting in a growth-oriented business plan that includes strategic acquisitions for Proxima AB.
Prata med transaktionsteamet
Relaterade transaktioner
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Lär dig merbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Lär dig merBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Lär dig mer